Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 2
2008 2
2009 5
2010 7
2011 3
2012 4
2013 15
2014 11
2015 7
2016 16
2017 11
2018 5
2019 8
2020 4
2021 5
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31056294

97 results

Results by year

Filters applied: . Clear all
Page 1
Are drug-eluting stents safer than bare-metal stents?
Jensen LO, Christiansen EH. Jensen LO, et al. Lancet. 2019 Jun 22;393(10190):2472-2474. doi: 10.1016/S0140-6736(19)31000-1. Epub 2019 May 2. Lancet. 2019. PMID: 31056294 No abstract available.
Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
Alfonso F, Pérez-Vizcayno MJ, García Del Blanco B, García-Touchard A, López-Mínguez JR, Masotti M, Zueco J, Melgares R, Mainar V, Moreno R, Domínguez A, Sanchís J, Bethencourt A, Moreu J, Cequier A, Martí V, Otaegui I, Bastante T, Gonzalo N, Jiménez-Quevedo P, Cárdenas A, Fernández C; under the auspices of the Interventional Cardiology Working Group of the Spanish Society of Cardiology. Alfonso F, et al. Circ Cardiovasc Interv. 2016 Jul;9(7):e003479. doi: 10.1161/CIRCINTERVENTIONS.115.003479. Circ Cardiovasc Interv. 2016. PMID: 27412868
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G; PRODIGY Investigators. Valgimigli M, et al. JACC Cardiovasc Interv. 2014 Jan;7(1):20-8. doi: 10.1016/j.jcin.2013.09.008. Epub 2013 Dec 11. JACC Cardiovasc Interv. 2014. PMID: 24332420 Free article. Clinical Trial.
Intravascular ultrasound assessment of minimum lumen area and intimal hyperplasia in in-stent restenosis after drug-eluting or bare-metal stent implantation. The Nordic Intravascular Ultrasound Study (NIVUS).
Jensen LO, Vikman S, Antonsen L, Kosonen P, Niemelä M, Christiansen EH, Kervinen K, Erglis A, Harnek J, Kumsars I, Thuesen L, Niemelä K. Jensen LO, et al. Cardiovasc Revasc Med. 2017 Dec;18(8):577-582. doi: 10.1016/j.carrev.2017.05.010. Epub 2017 May 12. Cardiovasc Revasc Med. 2017. PMID: 29066343
A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García Del Blanco B, Seidelberger B, Iñiguez A, Gómez-Recio M, Masotti M, Velázquez MT, Sanchís J, García-Touchard A, Zueco J, Bethencourt A, Melgares R, Cequier A, Dominguez A, Mainar V, López-Mínguez JR, Moreu J, Martí V, Moreno R, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C; RIBS V Study Investigators, under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology. Alfonso F, et al. J Am Coll Cardiol. 2014 Apr 15;63(14):1378-86. doi: 10.1016/j.jacc.2013.12.006. Epub 2014 Jan 8. J Am Coll Cardiol. 2014. PMID: 24412457 Free article. Clinical Trial.
97 results